CMA alleges collusion allowed 1,800% hike in Aspen drug pricing
09-10-2019
CMA accuses 4 pharma companies of anti-competitive conduct
24-05-2019
Sureeporn Teerasatean / Shutterstock.com
The UK Competition and Markets Authority (CMA) is investigating Essential Pharma over suspicions that the pharmaceutical company contravened competition law by proposing to withdraw the supply of Priadel, a lithium-based medication for bipolar disease.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Essential Pharma, Priadel, competition, DHSC, Camcolit, Competition and Markets Authority, bipolar drug, CMA
